Back to Journals » Patient Preference and Adherence » Volume 7

Effect of pill burden on dosing preferences, willingness to pay, and likely adherence among patients with type 2 diabetes

Authors Hauber AB, Han S, Yang JC, Gantz I, Tunceli K, Gonzalez JM, Brodovicz K, Alexander CM, Davies M, Iglay K, Zhang Q, Radican L

Received 30 January 2013

Accepted for publication 14 June 2013

Published 18 September 2013 Volume 2013:7 Pages 937—949

DOI https://doi.org/10.2147/PPA.S43465

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 5

A Brett Hauber,1 Steven Han,2,3 Jui-Chen Yang,1 Ira Gantz,2 Kaan Tunceli,2 Juan Marcos Gonzalez,1 Kimberly Brodovicz,2 Charles M Alexander,2 Michael Davies,2 Kristy Iglay,2 Qiaoyi Zhang,2 Larry Radican2

1Health Preference Assessment, Research Triangle Institute (RTI) Health Solutions, Research Triangle Park, NC, USA; 2Merck Sharp and Dohme Corporation, Whitehouse Station, NJ, USA; 3Temple University, Philadelphia, PA, USA

Purpose: To quantify willingness-to-pay (WTP) for reducing pill burden and dosing frequency among patients with type 2 diabetes mellitus (T2DM), and to examine the effect of dosing frequency and pill burden on likely medication adherence.
Patients and methods: Participants were US adults with T2DM on oral antihyperglycemic therapy. Each patient completed an online discrete-choice experiment (DCE) with eight choice questions, each including a pair of hypothetical medication profiles. Each profile was defined by reduction in average glucose (AG), daily dosing, chance of mild-to-moderate stomach problems, frequency of hypoglycemia, weight change, incremental risk of congestive heart failure (CHF), and cost. Patients were asked to rate their likely adherence to the profiles presented in each question. Choice questions were based on a predetermined experimental design. Choice data were analyzed using random-parameters logit. Likely treatment adherence was analyzed using a Heckman two-stage model.
Results: Of the 1,114 patients who completed the survey, 90 had lower dosing burden (<5 pills/day taken once/day or as needed) for all medications, and 1,024 had higher dosing burden (≥5 pills/day or more than once/day). Reduction in AG was valued most highly by patients. Hypoglycemia, chance of mild-to-moderate stomach problems, weight change, incremental risk of CHF, and daily dosing were less valued. Patients with higher current dosing burden had lower WTP for more convenient dosing schedules than patients with lower current dosing burden. Changes in dosing and cost impacted likely adherence. The magnitude of the impact of dosing on likely adherence was higher for patients with lower current dosing burden than for patients with higher current dosing burden.
Conclusion: Patients with T2DM were willing to pay for improvements in efficacy, side effects, and dosing. Patients' WTP for more convenient dosing depended on current dosing burden, as did the effect of these attributes on likely adherence.

Keywords: discrete-choice experiment, conjoint analysis, willingness to pay, adherence, type 2 diabetes mellitus, oral antihyperglycemic therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment

González JM, Ogale S, Morlock R, Posner J, Hauber B, Sommer N, Grothey A

Cancer Management and Research 2017, 9:149-158

Published Date: 27 April 2017

Patient preferences for reducing toxicities of treatments for gastrointestinal stromal tumor (GIST)

Hauber AB, Gonzalez JM, Coombs J, Sirulnik A, Palacios D, Scherzer NJ

Patient Preference and Adherence 2011, 5:307-314

Published Date: 24 June 2011

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

A novel preparation method for silicone oil nanoemulsions and its application for coating hair with silicone

Hu Z, Liao M, Chen Y, Cai Y, Meng L, Liu Y, Lv N, Liu Z, Yuan W

International Journal of Nanomedicine 2012, 7:5719-5724

Published Date: 12 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010